Owkin and BeOne Medicines Sign Clinical Supply Agreement for Tislelizumab in INVOKE Trial of OKN4395
Owkin official newsroom · Indexed industry source record · Source published: Mon Jun 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:24 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
BeOne Medicines will supply tislelizumab, its PD-1 inhibitor, to Owkin's ongoing INVOKE Phase 1a/1b trial of OKN4395 in patients with advanced solid tumors (NCT06789172). The agreement opens a combination arm pairing OKN4395 with tislelizumab, releasing two distinct immunosuppressive brakes on the anti-tumor immune response simultaneously. Paris - June 1, 2026 - Owkin, the Agentic AI company pione
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.